ロード中...
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. T...
保存先:
| 出版年: | Case Rep Oncol Med |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hindawi
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7166298/ https://ncbi.nlm.nih.gov/pubmed/32318300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/4936846 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|